TrialInvestigational new drugs2020

Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.

Linlin Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.